Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results
Cancer
 

Click here to go back to your search results.

Lung Cancer treatment details. Biologic therapy. Chemotherapy. Robert H. Lurie Comprehensive Cancer Center, Chicago, IL, United States



Survival: 12.6 months
   
Toxicity Grade: 5
   
Treatments: Biologic therapy
Chemotherapy
   
Drugs: Pemetrexed
Country: United States
   
City/State/Province: Chicago, IL
   
Hospital: Robert H. Lurie Comprehensive Cancer Center
   
Journal: Link
   
Date: 12/2013

Description:
Patients:
This phase 3 study involved nonsquamous non-small cell lung cancer patients who were divided into two separate treatment groups. Group A consisted of 472 patients with a median age of 64.6 years and 53.2% male. Group B had 467 patients with a median age of 64.9 years and 53.3% male.

Treatment:
Patients in group A received chemotherapy with pemetrexed and carboplatin and biologic therapy with bevacizumab.

Patients in group B received chemotherapy with paclitaxel and carboplatin and biologic therapy with bevacizumab.

Toxicities:
Treatment-related deaths due to bleeding, cardiac disorders, stroke, infection, and respiratory distress were reported for group A. Grade 3-4 neutropenia, thrombocytopenia, and anemia were also reported.

Treatment-related deaths due to bleeding, cardiac disorders, and stroke were reported for group B. Grade 3-4 nerve toxicity and neutropenia were also reported.

Results:
The median overall survival for groups A and B was 12.6 and 13.4 months, respectively.

Support:
This study was supported by Eli Lilly and Genentech.

Correspondence: Dr. Jyoti D. Patel; email: jd-patel@northwestern.edu

E-mail to a Friend Email Physician More Information